Erasca, Inc. (ERAS) Financials
ERAS Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-09-30 | 419.4 million | 80.4 million |
2023-06-30 | 440.7 million | 78.0 million |
2023-03-31 | 467.5 million | 81.1 million |
2022-12-31 | 514.9 million | 103.1 million |
ERAS Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-09-30 | -24.4 million | 6.2 million |
2023-06-30 | -26.2 million | 7.0 million |
2023-03-31 | -47.6 million | 6.8 million |
2022-12-31 | -27.2 million | 5.4 million |
ERAS Net Income
No data available :(
ERAS Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-09-30 | 343.6 million | - | 56.8 million |
2023-06-30 | 317.2 million | - | 57.6 million |
2023-03-31 | 389.7 million | - | 58.1 million |
2022-12-31 | 435.6 million | - | 55.1 million |
ERAS Shares Outstanding
ERAS Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-09-30 | 240000 | 25.2 million | 9.4 million | - |
2023-06-30 | 247000 | 26.2 million | 9.8 million | - |
2023-03-31 | 21.2 million | 27.6 million | 9.4 million | - |
2022-12-31 | 864000 | 29.4 million | 8.7 million | - |
ERAS Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-09-30 | - | 941000 |
2023-06-30 | - | 955000 |
2023-03-31 | - | 894000 |
2022-12-31 | - | 933000 |
ERAS
Price: $2.18
52 week price:
Earnings Per Share: -0.83 USD
P/E Ratio: -1.02
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Volume: 393750
Market Capitalization: 346.0 million